1-2 of 2
Merlin Efraim, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

David J. Kuter, MD, Merlin Efraim, MD, Jiri Mayer, MD, Vickie McDonald, MD, Robert J. Bird, FRACP,FRCP,FRCPA,MBBS,MRCP, Thomas Regenbogen, MD, Mamta Garg, MD FRCP, FRCPath, Zane Kaplan, MBBS(Hons) BMedSc(Hons) PhDFRACP FRCPA, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-134932
Published: 2020
Journal Articles

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

David J. Kuter, Ralph V. Boccia, MD, Eun-Ju Lee, MD, Merlin Efraim, MD, Nikolay Tzvetkov, MD, Jiri Mayer, MD, Marek Trněný, MD, Milan Kostal, MD, Roman Hajek, MD, Vickie McDonald, MD, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 87.
https://doi.org/10.1182/blood-2019-122336
Published: 2019